Latest News & Features
Asia
In India, there are two core areas of the antibody patenting field that are unsettled and need correcting, as Archana Shanker and Nupur Maithani of Anand and Anand explain. 31 May 2018
Americas
Research and development, strong IP rights and good international relations are all factors in Brazil’s rise as a soybean-producing powerhouse, as Gabriel Di Blasi and Matheus Gil do Amaral of Di Blasi Parente & Associados report. 29 May 2018
Asia
The Indian Patent Office has attempted to bridge the divide between the laws on patents and biological diversity, but instead it created a maze of problems, says Vidisha Garg of Anand and Anand. 15 May 2018
Africa
There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested. 8 May 2018
Americas
Courts have not always been able to appreciate the complexities around antibody patents, causing problems for innovation and investment, says Eli Lilly patent counsel Duane Marks in an interview with LSIPR. 17 April 2018
article
Variable sequence IP is fertile ground for potential validity challenges based on prior art or lack of enablement, as Ellen Sherin of GQ Life Sciences reports. 12 April 2018
Asia
The ChinaBio Partnering Forum, which will be held in Suzhou from April 25 to 26, is celebrating its tenth anniversary and is expected to attract pharma and biotech companies from around the world. 12 April 2018
Genetics
There is a complex relationship between the advancing global bioeconomy and the regulatory frameworks covering access to genetic resources, says Diana Jungmann of Di Blasi Parente & Associados. 26 March 2018
Americas
The IP team at AstraZeneca must “ruthlessly” prioritise how it spends time and resources, its vice president of global IP explained in an interview. 8 March 2018
Americas
The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences. 6 March 2018